Brief screening tools for early dementia risk are essential in primary care. A 2026 study by You et al. evaluated the AD8 informant questionnaire in older Chinese-speaking adults in Australia, mapping how cognitive, functional, social, and language-barrier risks stack before dementia is formally diagnosed.1 Research Highlights The AD8 dementia screening interview is an 8-item informant-based …
Patients with schizophrenia have substantially elevated dementia risk compared to the general population — roughly 2-3 times the age-adjusted rate — but the specific drivers within the schizophrenia population have been less well characterized. A 2026 case-control study by Ho et al. used population-based data to identify which factors specifically elevate dementia risk among schizophrenia …
Cognitive fluctuations are a defining feature of dementia with Lewy bodies (DLB), helping distinguish it from Alzheimer’s disease — but they remain notoriously difficult to characterize and measure. A 2026 review by Mahajan and colleagues maps the neurobiology, measurement, and clinical implications of fluctuations across the Lewy body spectrum.1 Research Highlights Cognitive fluctuations are episodes …
Multiple system atrophy is a rapidly progressive neurodegenerative disease with no proven disease-modifying therapy. A 2026 review by Jeong and colleagues tracks two decades of repurposed-drug trials, with one recent positive Phase 2 result.1 Research Highlights Multiple system atrophy (MSA) is a fatal α-synuclein disorder distinct from Parkinson’s disease. It progresses faster than PD (median …
The risperidone-stroke link in dementia is one of the longest-running safety signals in geriatric psychiatry, anchoring the FDA’s 2005 black-box warning on atypical antipsychotic mortality. Popular framing reduces it to “antipsychotics cause stroke in dementia” — a true sentence that flattens a multi-axis decision. Choma’s 2025 analysis of UK primary care records is the largest …
Parkinson’s disease is the second most common neurodegenerative disorder, affecting around 10 million people worldwide. The mental-health burden is heavy: depression affects 40-50% of patients9, anxiety 30-40%, sleep disorders most patients eventually, and dementia about a third of long-duration cases. Standard treatment with levodopa controls motor symptoms but doesn’t slow the underlying neurodegeneration. The clinical …
Loneliness raises measured risk of Alzheimer’s, suicidal ideation, and completed suicide. The associations are documented; the precise magnitudes are not.